Puma Biotechnology, Inc.

NasdaqGS:PBYI Stok Raporu

Piyasa değeri: US$144.7m

Puma Biotechnology Yönetim

Yönetim kriter kontrolleri 3/4

Puma Biotechnology's CEO is Alan Auerbach, appointed in Sep 2010, has a tenure of 14.17 years. total yearly compensation is $2.94M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 14.05% of the company’s shares, worth $20.33M. The average tenure of the management team and the board of directors is 6.4 years and 8 years respectively.

Anahtar bilgiler

Alan Auerbach

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi29.8%
CEO görev süresi14.2yrs
CEO sahipliği14.1%
Yönetim ortalama görev süresi6.4yrs
Yönetim Kurulu ortalama görev süresi8yrs

Son yönetim güncellemeleri

Recent updates

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Aug 04

CEO Tazminat Analizi

Alan Auerbach'un ücretlendirmesi Puma Biotechnology'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$9m

Mar 31 2024n/an/a

US$15m

Dec 31 2023US$3mUS$878k

US$22m

Sep 30 2023n/an/a

US$4m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

US$5m

Dec 31 2022US$3mUS$852k

US$2k

Sep 30 2022n/an/a

US$10m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$49m

Dec 31 2021US$18mUS$827k

-US$29m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$4mUS$834k

-US$60m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$4mUS$780k

-US$76m

Sep 30 2019n/an/a

-US$95m

Jun 30 2019n/an/a

-US$92m

Mar 31 2019n/an/a

-US$99m

Dec 31 2018US$6mUS$757k

-US$114m

Sep 30 2018n/an/a

-US$147m

Jun 30 2018n/an/a

-US$210m

Mar 31 2018n/an/a

-US$243m

Dec 31 2017US$3mUS$733k

-US$292m

Tazminat ve Piyasa: Alan's total compensation ($USD2.94M) is above average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Alan's compensation has been consistent with company performance over the past year.

CEO

Alan Auerbach (54 yo)

14.2yrs

Görev süresi

US$2,944,748

Tazminat

Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman since October 4, 2011 and serves as its Chief Executive Officer, President and Secretary since September...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Alan Auerbach
Founder14.2yrsUS$2.94m14.05%
$ 20.3m
Maximo Nougues
CFO & Principal Accounting Officer6yrsUS$1.23m0.24%
$ 340.4k
Douglas Hunt
Chief Regulatory Affairs6.8yrsUS$1.02m0.19%
$ 273.7k
Jeffrey Ludwig
Chief Commercial Officer4.7yrsUS$1.38m0.17%
$ 240.0k
Mariann Ohanesian
Senior Director of Investor Relations13yrsVeri yokVeri yok
Bo Chao
Senior Vice President of Clinical Development1.1yrsVeri yokVeri yok

6.4yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: PBYI's management team is seasoned and experienced (6.4 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Alan Auerbach
Founder13.1yrsUS$2.94m14.05%
$ 20.3m
Jay Moyes
Lead Independent Director12.6yrsUS$172.27k0.043%
$ 62.9k
Michael Miller
Independent Director6.8yrsUS$162.90k0.041%
$ 59.0k
Troy Wilson
Independent Director11.1yrsUS$172.27k0.0018%
$ 2.6k
Alessandra Cesano
Independent Director2.3yrsUS$152.27k0.055%
$ 79.7k
Adrian Senderowicz
Independent Director9.3yrsUS$164.77k0%
$ 0
Allison Dorval
Independent Director3.3yrsUS$154.77k0.067%
$ 97.3k
Brian Stuglik
Independent Director4.3yrsUS$161.65k0.10%
$ 144.7k

8.0yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PBYI's board of directors are considered experienced (8 years average tenure).